Clinical Trials Logo

Clinical Trial Summary

This is a phase 1, dose-escalation, and multidose study, aiming to investigate the tolerability, safety and pharmacokinetics of Anfibatate in healthy subjects. The study is divided into 2 intravenous single groups and 3 continuous administration groups. The dose of Anfibatate from 5 IU/60kg to 7 IU/60kg in intravenous single groups. The dose of Anfibatate from 0.002 IU/kg/h, 0.004 IU/kg/h to 0.008 IU/kg/h in continuous administration groups.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04404790
Study type Interventional
Source Lee's Pharmaceutical Limited
Contact
Status Suspended
Phase Phase 1
Start date September 2020
Completion date May 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04971356 - 1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon N/A
Not yet recruiting NCT06243133 - Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis Phase 4
Recruiting NCT06269432 - Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Acute Ischemic STROKE(PATH-STROKE) Phase 4
Recruiting NCT05852197 - Effect of Anticoagulant Drug Intervention on Postoperative MALE and MACE in Patients With PAD